Drugs / Alfimeprase
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00499902 | Jun 2007 → May 2008 | ischemic stroke | ARCA Biopharma, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00073554 | Jun 2003 → ? | arterial occlusion, peripheral vascular disease, thrombotic disease | ARCA Biopharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00073515 | — | — | ARCA Biopharma, Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT00338585 | Apr 2006 → Mar 2007 | arterial occlusion | ARCA Biopharma, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00322270 | Jan 2006 → ? | thrombotic disease, vascular occlusion disorder, venous thromboembolism | ARCA Biopharma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00346424 | Sep 2005 → Oct 2006 | thrombotic disease, venous thromboembolism | ARCA Biopharma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00115999 | Apr 2005 → Feb 2007 | arterial occlusion | ARCA Biopharma, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alfimeprase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00499902 ↗ |
| Known as | Alfimeprasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108893 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2108893 ↗ |
| Route | Other | “intra-thrombus alfimeprase” NCT00115999 ↗ |